Hemgenix has been given ‘conditional authorisation’. Consequently the eu Medicines Agency decided that the advantages of Hemgenix are higher than its threats, but the corporation must supply further evidence just after authorisation.In accordance with the clinical specialists consulted by CADTH, there are several unmet demands for hemophilia B.… Read More